Tiopronin Tablets are widely prescribed in several countries for the treatment of acute and chronic Hepatitis B (HB), and for the relief of drug-induced liver injury. However, this drug can cause stomach irritation therefore its use and patient compliance may be limited by the side effects. To address this, China Pharma has developed Tiopronin Capsules with an enteric coating to decrease the stomach mucosal irritation associated with Tiopronin. As a result, China Pharma's Tiopronin Enteric-Coated format improves liver function while protecting the stomach.
Ms.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company with
rapidly growing profit that develops, manufactures, and markets treatments for
a wide range of high incidence and high mortality conditions in
Safe Harbor Statement: Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.
* Source: MEDICINE ECONOMIC NEWS Jun. 24, 2005 For more information, please contact: China Pharma Holdings, Inc. Diana Huang Tel: +86-898-6681-1730 Email: hps@chinapharmaholdings.com The Ruth Group Sara Ephraim Tel: +1-646-536-7002 Email: sephraim@theruthgroup.com
SOURCE China Pharma Holdings, Inc.